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global economic and humanistic burden. The condition presents a
real challenge in Asia, which accounts for more than 60% of individ-
uals with DM globally. Health technology assessment (HTA) is a ﬁeld
of scientiﬁc research used to inform policy and clinical decision
making relating to the introduction and diffusion of health technol-
ogies. Objectives: This article, examines the present use and pre-
dicted evolution of HTA with respect to pricing and reimbursement of
drugs in mainland China, Japan, South Korea, and Taiwan. It makes
speciﬁc reference to important assessment considerations for DM
therapies, which should assist key stakeholders in choosing which
data to capture, and what approaches to use, to help quantify the
value of treatment. Methods: The ﬁndings are informed by two
Advisory Board discussions, a literature review, and the authors’
personal experience. Results: HTA already has a key role in South
Korea and Taiwan, with current systems undergoing importantee front matter Copyright & 2014, International S
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yet formally utilized, although this appears likely to change.
Several elements are important for HTA to be meaningful and
impactful for DM therapies, including a clear, transparent analytical
framework for HTA that includes all relevant costs and outcomes;
availability of local DM epidemiologic, economic, and quality-of-life
data; acceptance of modeling as a core methodology; availability of
real-life patient data; and recognition of speciﬁc evidence require-
ments associated with biosimilars. HTA has the potential to assist
payors in making informed decisions about the coverage of DM
medications.
Keywords: Asia, diabetes mellitus, health technology assessment,
pricing, reimbursement.
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Asia accounts for more than 60% of the global population of people
with diabetes mellitus (DM) [1]. In the Western Paciﬁc region, which
includes mainland China, Japan, South Korea, and Taiwan, there are
131.9 million people (8.5% of the adult population) who have DM,
and this region also has the highest number of deaths attributable to
DM: 15% of all deaths in 2011 were related to DM [2]. The prevalence
of type 2 DM (T2DM) is increasing; this is being driven by a number
of factors, including economic development, dietary changes, and
increasingly sedentary lifestyles [3,4]. Compared with people in
other regions, people in Asia tend to develop diabetes with a lesser
degree of obesity and at younger ages, suffer longer from its
complications, and die earlier [5]. There is great diversity in social
and economic development, population size, health care system,language, religion, and culture across Asia [6]. In this article, we
focus speciﬁcally on mainland China, Japan, South Korea, and
Taiwan, which, despite their differences, all commonly face the
growing challenge of DM.
Despite the existing evidence on the importance of intensive
glycemic management [7–9], DM control is suboptimal. Studies in
mainland China, South Korea, and Taiwan report that the
proportion of patients with DM achieving a glycated hemoglobin
level of less than 7.0% ranges from 32% to 44%; in Japan, only 34%
of the patients with DM have been reported to have a glycated
hemoglobin level of less than 6.5% [10–13].
DM imposes substantial demands on health care resources: it is
estimated that the total global health care expenditure on DM in 2010
was at least US $376 billion, and this ﬁgure is expected to increase to
US $490 billion by 2030 [4]. The International Diabetes Federation hasociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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20 to 79 years, expressed in US $ and in international dollars—a US
dollar that is adjusted to account for differences in purchasing power
[4]. National-level cost data for mainland China, Japan, and South
Korea are presented in Table 1. A separate study reported that the
total cost of DM to society in Taiwan is approximately US $2.96
billion, equivalent to approximately 0.8% of the gross domestic
product [14].
The economic burden of DM is driven primarily by the cost of
complications [15]. In a Japanese study, the medical costs for
patients with DM with nephropathy were 2.1-fold higher than for
those without nephropathy, while evidence of retinopathy and
neuropathy was associated with 2.6-fold and 3.3-fold higher costs,
respectively [16]. A Korean study reported that annual direct medical
costs for a patient with only microvascular, only macrovascular, or
both macrovascular and microvascular complications were 1.5, 2.7,
and 2.0 times higher than the medical costs for patients without
these complications [17].
Health technology assessment (HTA), as deﬁned by the Inter-
national Network of Agencies for Health Technology Assessment,
is a multidisciplinary ﬁeld of policy analysis, studying the medical,
economic, social, and ethical implications of development, diffu-
sion, and use of health technology [18]. It is accepted that through
beneﬁt-harm assessment and economic evaluation, a major use of
HTA is to inform pricing, access, and reimbursement decisions.
The main focus of our article, therefore, is to report whether, and if
so how, HTA is presently used as part of the decision-making
process to inform coverage and funding decisions of DM medi-
cations in mainland China, Japan, South Korea, and Taiwan, and
to discuss how this could evolve in the future. The general themes
included in this article were informed by discussions at Advisory
Boards held in Hong Kong (October 2011) and Tokyo (October 2011)
and were further reﬁned through review of the published literature
and the personal experience of the authors. We provide a brief
overview of evidence-based assessment systems in mainland
China, Japan, South Korea, and Taiwan, and discuss the implica-
tions of these systems on the pricing and reimbursement of DM
medications. We anticipate that this overview will help to ensure
that relevant outcomes and perspectives are included in future
HTA analyses of DM treatment strategies and medications and
that it will also assist manufacturers in choosing which data to
capture to help quantify the value of their therapies for future
evidence-based assessment and HTA analyses.Overview of the Role of HTA in Pricing and Reimbursement
of Drugs
Table 2 summarizes the current process for pricing and reimburse-
ment for drugs, the role that HTA has in the current health care
systems, and how this is expected to change in the future in
mainland China, Japan, South Korea, and Taiwan. HTA already has
a key role in the assessment of medications in South Korea and
Taiwan. In contrast, HTA is not yet formally utilized inTable 1 – Cost of DM in mainland China, Japan, and
South Korea [4].
Region National-level cost estimate (000)
US $ ID
Mainland China 4,968,697 19,322,712
Japan 22,150,915 18,846,385
South Korea 4,130,467 5,361,541
DM, diabetes mellitus; ID, international dollars.reimbursement and price decision making in mainland China or
Japan, although this may change in the future.
In South Korea, economic evidence is required for a drug to be
included in the Positive List Scheme (PLS). There is no benchmark for
the incremental cost-effectiveness ratio because the Health Insur-
ance Review Agency (HIRA) makes ﬂexible judgments alongside
other criteria such as disease severity and innovation. Nevertheless,
a benchmark of around one times the gross domestic product per
capita (US $26k, 2007) has evolved as a general reference value [19].
An assessment of 47 evaluations that were approved by HIRA after
the introduction of the PLS found that, on average, 14 of the 20 items
on the HIRA checklist for quality assessment of pharmacoeco-
nomic evaluations submitted for coverage decisions were fulﬁlled.
Where cost-utility analysis was undertaken, the incremental cost-
effectiveness ratios from a societal perspective ranged from domi-
nant to US $28k per quality-adjusted life-year for “recommended”
submissions (n ¼ 6), US $8k to US $20k per quality-adjusted life-year
for “recommended with restricted use” submissions (n ¼ 4), and US
$13k to US $59k per quality-adjusted life-year for “not recommended”
submissions (n¼ 3) [19]. Bae and Lee [20] reported that by the time of
their published analysis in 2009, only 10 of these 47 drugs were
actually priced and listed by the National Health Insurance Corpo-
ration [20]. The separation of the reimbursement recommendation
by HIRA and the price/volume negotiation between the technology
manufacturer and the National Health Insurance Corporation has led
to claims that there is administrative duplication. In addition, the
“listing lag” has generated skepticism from the industry [21].
Signiﬁcant changes are currently ongoing in Taiwan since the
second generation of the National Health Insurance system was
implemented in 2013. The drug manufacturer submits the dossier
according to the structure speciﬁed by the National Health
Insurance Administration (NHIA) (see Table 2). The NHIA sends
the dossier to the National Institute of HTA (previously the HTA
group within the Center for Drug Evaluation), which conducts an
independent assessment using comparative effectiveness and
economic evidence, as well as undertaking its own budget impact
analysis. The assessment report is then sent to the NHIA, where
an expert consultation group conducts the initial appraisal. The
new system introduced in 2013 involves a Pharmaceutical Beneﬁt
and Price Schedule Stakeholders’ meeting between the NHIA and
public and medical professional representatives, who will make
the ﬁnal value judgment on the recommendations put forward by
the expert consultation group. The judgment arising from the
Stakeholders’meeting is sent to the NHIA for a ﬁnal decision. The
price is initially recommended by the expert consultation group,
and further approval is given at the Stakeholders’ meeting before
the recommendation is sent to the NHIA. Similar to the previous
system, the stronger the evidence for the drug, the higher the
support for inclusion in the PLS. In addition, there are incentives
offered for the use of local economic data, whereby a price
premium of up to 10% is available if data from a local pharma-
coeconomic study are submitted in the dossier.
In bothmainland China and Japan, there are indications that HTA
will have a future role in access to medicines (Table 2). The structure
that this will take within the overall process of pricing, reimburse-
ment, and access environment, however, is still under discussion.
The Assessment of DM Medications within an HTA System
A set of 15 best practice principles has been proposed that can be
used to assess existing HTA programs. These are organized into four
categories: structure of HTA programs, methods of HTA, processes
for conducting an HTA, and use of HTAs in decisionmaking [22]. It is
not our aim to apply these principles to the geographies of interest,
but rather to focus on some key features of an assessment frame-
work that would have speciﬁc relevance to the appraisal of DM
therapies. The list is not meant to be exhaustive and is intended to
Table 2 – An overview of the current drug pricing and reimbursement system, the role of HTA, and expected changes to the drug pricing and
reimbursement system relating to HTA in mainland China, Japan, South Korea, and Taiwan.
Geographic
area
Current drug pricing and reimbursement
system
Role of HTA in health care system Expected changes relating to the use of HTA in
drug pricing and reimbursement
Mainland
China
The Ministry of Human Resources and Social Security
(MoHRSS) develops the National Reimbursed Drug List
(NRDL). An expert evaluation mechanism is used for
NRDL product assessment, screening, revision, and
selection. Priorities are given to those products that
are clinically demanded, safe, effective, and reasonably
priced. Provinces can adjust drug prices in the NRDL by
up to 15% with a similar expert evaluation mechanism.
The Ministry of Health (MoH) develops the National
Essential Drug List (NEDL). This is incorporated with
the NRDL, with higher reimbursement levels than
nonessential drugs in the NRDL.
The National Development and Reform Commission
(NDRC) is responsible for drug pricing. The NDRC sets
maximum retail prices for medicines included in the
NRDL, and this is largely based on a mark-up above the
average production cost declared by manufacturers. In
addition, they can set a price premium where there is
superior quality, effectiveness, or a unique advantage.
There is, however, currently no formal
pharmacoeconomic analysis used in the process.
HTA-related activities have been ongoing in mainland
China since the 1990s; however, these have been
research based and have not been used to affect policy
[40].
The Key Laboratory of Health Technology Assessment
(KLHTA) was established in 2004. This has a number of
responsibilities, including HTA research and
dissemination, education, and training, and since 2007
has been a World Health Organization (WHO)
Collaborating Center for Health Technology Center and
Management [40]. In October 2009, the National Institute
for Health and Care Excellence (NICE) signed a
memorandum of understanding with the MoH of
mainland China, with the aim of supporting the Chinese
government with ongoing rural health reform. With the
Department for International Development (DFID),
WHO, and World Bank support, NICE is helping the MoH
to build capacity (institutional and technical) and to
pilot the development/adaptation of evidence-informed
clinical standards for best practice, taking into account
efﬁciency and equity considerations [41].
The China National Health Development Research Centre
is also playing a coordinating role in HTA training and
capacity building.
There are strong indications that HTA will be used in
future listing, pricing, and reimbursement of
pharmaceuticals. The 2009 NRDL revision plan states
that costs and beneﬁts of products in each base
subcategory will be compared using
pharmacoeconomic principles (insulin, e.g., is a base
subcategory of “insulin and other blood sugar–
inﬂuencing drugs”) [42].
In the 2013/ 2014 NRDL review, and in the future
negotiation process for the Provincial Reimbursement
Drug List (PRDL), pharmaceutical companies may be
allowed to submit HTA data for premium-priced
innovative drugs.
In addition, the NDRC in the “Guideline for Reform of
Drug and Medical Service Pricing” [43] has expressed
that pricing for substitute and innovative drugs should
gradually adopt pharmacoeconomic evaluation.
Japan After regulatory approval for a drug is obtained, the
manufacturer requests that the Ministry of Health,
Labor and Welfare (MHLW) add the drug to the positive
list for reimbursement through the public insurance
system, and a decision is made within 90 d [44].
The pricing of new drugs is the responsibility of the
Central Social Insurance Medical Council (“Chuikyo”),
an advisory committee under the MHLW. There are
two methods to set baseline prices of new drugs, the
comparison method and the cost-up method [45].
The comparison method is used if drugs similar to the
new drug are available. The base price is set equal to
the comparator’s price (with the comparator’s selection
criteria based on indications, effect, and pharmacologic
action), with premiums applicable for innovation and
usefulness (5%120%) (Table 3), pediatric use
(5%20%), and market size (10%20%).
For the period 1997–2008, only 2 (0.5%) drugs secured an
Innovation premium, with 10 (2.5%) obtaining a
Historically, there has been very limited use of HTA in
Japan [21]. Pharmaceutical companies have been able to
submit data relating to cost-effectiveness when
applying for a drug price through the National Health
Insurance drug price listing system since 1992 [46].
However, there has been no formal structure to reﬂect
the cost-effectiveness of the drug within the pricing
system.
A recent survey by the Organisation for Economic Co-
operation and Development (OECD) outlines the need
for improved efﬁciency in health care delivery,
explaining that boosting spending under the current
framework would exacerbate the ﬁscal situation [47].
A number of health care reforms are ongoing, and it is
expected that HTA will have a future role in the
assessment of new technologies, with drug pricing
reform being one of the key drivers.
In 2011, the MHLW announced that cost-effectiveness
analysis would be introduced on a trial basis from 2014
for policymaking, including reimbursement pricing in
medical devices, procedures, and drugs.
However, this has now been postponed to 2016 or later.
Chuikyo is currently considering how HTA might be
integrated into Japan's system for drug and device
pricing and reimbursement.
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Usefulness I premium, and 68 (16.8%) achieving a
Usefulness II premium [45]. If there is no similar drug
for comparison, the base price is calculated according
to actual costing data (costs of research and
development as well as costs of production and
distribution), as supplied by the company [44].
After the base price for the new drug is determined, a
foreign price adjustment is undertaken to minimize
the price differential between Japan and other
countries [44].
Every 2 y after listing, there is a repricing analysis based
on market activity. There is currently little to no
opportunity for a manufacturer to submit new
evidence in defense of the price— this can be
performed only during market expansion repricing,
which is a separate activity with different triggers.
South Korea The Korean National Health Insurance (KNHI) system
funds drugs that are on the PLS.
The PLS was introduced by the Government of South
Korea as part of a Drug Expenditure Rationalization
Plan [39].
Reimbursement and price decisions for new drugs are
separated. The Health Insurance Review and
Assessment Service (HIRA) is responsible for
reimbursement assessment, and the NHIC negotiates
the price with the pharmaceutical company [48].
When the new PLS was implemented in 2007, South Korea
became the ﬁrst Asian economy to require economic
evidence for drug reimbursement [20].
In the process of listing a new drug, the manufacturer
makes an application that is reviewed by HIRA, which
also sources additional data and expert opinion. HIRA
has published guidelines for submission that are
publicly available (but not translated into English). HIRA
evaluates the evidence and communicates the review
results to the Drug Reimbursement Evaluation
Committee (DREC) within HIRA, which then makes a
recommendation on listing (positive recommendation,
rejection, or restriction by indication). This decision is
informed by cost-effectiveness data, clinical usefulness,
the availability of alternatives, the severity of the
condition to be treated, the budgetary impact,
assessments from other countries, and the uncertainty
of the evidence presented [20].
Based on HIRA’s assessment and international price
referencing, the NHIC negotiates with the company on
price. If the negotiation fails, the drug will not be placed
on the PLS.
The HTA framework in Korea has not had any major
changes since its inception in 2007. However, there
have been some recent reﬁnements in the methods
outlined in the Pharmacoeconomic Submission
Guidelines. For example, there are new guidelines for
indirect comparison methodology, intended to help
researchers use proper methods to assess clinical
beneﬁts. This is important because, historically, there
was an excessive dependence on expert opinion to
estimate the clinical beneﬁts of new medical
technologies. In addition, transparency of the review
process is increasing with the availability of a
preconsultation with HIRA reviewers. This interaction
should help those submitting a dossier to identify data
requirements early in the data preparation stage.
A number of future changes are anticipated in the Korean
HTA framework. More ﬂexible use of ICER thresholds
may allow for slightly higher thresholds for selected
technologies that manage severe diseases. In addition,
the use of risk-sharing modules in reimbursement
decisions for selected new technologies is now under
consideration by the NHI reimbursement authority,
although the ultimate role of these modules would be
expected to evolve over time within the Korean HTA
system.
Taiwan The reimbursement of drugs is determined by the
National Health Insurance Administration (NHIA),
which sits within the Ministry of Health and
Welfare (MHW).
In Taiwan, HTA is undertaken for all new drugs for which
reimbursement is sought through the NHI program.
A number of new developments were implemented when
the second-generation NHIA law was passed in 2013.
Patient involvement as part of the HTA process is written
into the new mechanism but a process for
implementation is currently lacking. The NHIA is
preparing a template that could be used for patient
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Table 2 – continued.
Geographic
area
Current drug pricing and reimbursement
system
Role of HTA in health care system Expected changes relating to the use of HTA in
drug pricing and reimbursement
Following a positive appraisal by the NHIA, the drug is
added to the National Health Insurance (NHI)
formulary, after which it can be prescribed in any
health care facility in Taiwan. A co-payment is
required; this is determined by the price of the drug
and is usually 20% of the drug price. If the drug is not
listed, the patients can self-pay if they wish.
The drug price is set by the NHIA according to the
formula prepared by the NHIA staff and is determined
in the appraisal meeting by the committee members.
A new HTA process and a new committee for drugs,
medical services, and medical devices was formed in
April 2013.
The reimbursement process (which now includes devices)
involves three stages: 1) an HTA review by the NHIA,
undertaken through the National Institute of HTA; 2)
scientiﬁc judgment by an expert appraisal group; and 3)
a recommendation on drug listing for the NHIA
following the PBPS Stakeholders’ meeting, which
consists of various agencies, experts/scholars, the
insured, employers, and health care providers.
The HTA process involves analysis of comparative
effectiveness, pharmacoeconomics, and budget impact,
as well as consideration of the social, legal, and social
aspects of treatment.
The National Institute of HTA gathers evidence from other
HTA bodies, such as NICE, the Australian
Pharmaceutical Beneﬁts Advisory Committee (PBAC),
and the Canadian Agency for Drugs and Technologies in
Health (CADTH). The group searches the published
literature for clinical and economic data on the drug.
Using this evidence, and expert input if required, the
group prepares a review within 42 d that includes an
assessment of comparative effectiveness,
pharmacoeconomics, and a budget impact model (BIM).
This is based on evidence from the manufacturer’s
submission, existing HTA reports, and the published
literature rather than a stand-alone analysis (as is the
case for the BIM). This report is sent to two reviewers on
the Drug Expert Group who develop their own short
(1–2 page) report, which is used by the PBPS committee
to make listing, coverage, and pricing recommendations.
Price incentives are offered, including the use of data from
a local pharmacoeconomic study (up to 10%), improved
efﬁcacy (up to 15%), better safety (up to 15%), and greater
convenience (up to 15%).
groups to submit evidence.
HTA, health technology assessment; ICER, incremental cost-effectiveness ratio; PBPS, Pharmaceutical Price and Beneﬁt Schedule.
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Table 3 – Level of premium and criteria for Innova-
tiveness and Usefulness premiums in Japan [49].
Type of
premium
Level of
premium
Criteria
Innovativeness 70%–120% Applied to new products in
the NHI price lists meeting
all the following
requirements:
1. The newly entered drug has a
clinically meaningful new
mechanism of action.
2. The newly entered drug has
been shown objectively to
have greater efﬁcacy and
safety than existing
(comparator) drugs in the
same class.
3. The newly entered drug has
been shown objectively to
improve the treatment of the
indicated disease or trauma.
Usefulness I 35%–60% Applied to new drug products
in the NHI price lists that
meet two of the three
requirements listed above
Usefulness II 5%–30% Applied to new products in
the NHI price lists that meet
one of the following
requirements (excluding
products already covered by
Innovativeness or
Usefulness I premium):
1. The newly entered drug has a
clinically meaningful new
mechanism of action.
2. The newly entered drug has
been shown objectively to
have greater efﬁcacy and
safety than existing
(comparator) drugs in the
same class.
3. The newly entered drug has
been shown objectively to
offer, as a result of
formulation improvement,
greater than therapeutic
usefulness than other drugs
in the same class.
4. The newly entered drug has
been shown objectively to
improve the treatment of the
indicated disease or trauma.
NHI, National Health Insurance.
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are important for HTA to be meaningful and impactful for DM
therapies now and in the future Table 3.1. A clear, transparent analytic framework for HTA that
incorporates appropriate methods for assessing costs and
beneﬁts
It is important that a transparent analytic framework for HTA is
in place and that the methods are clearly speciﬁed and, ideally,have been developed through a process of consultation with the
various stakeholders (health care providers, patients and patient
advocates, government agencies, pharmaceutical industry).
There are some challenges with the current systems in which
HTA inﬂuences access to medicines, and these have implications
for the assessment of DM drugs. In South Korea, a key issue has
been the choice of the comparator, with different alternatives
proposed by the company and HIRA, and attempts are being
made to resolve this by initiating a prior consultation system [20].
The deﬁnition of clinical value or utility will be a key area for
future discussion, not just in Asia but also across the world. One
example comes from England, where the National Institute for
Health and Care Excellence will have a central role in the future
value-based pricing system for the National Health Service. This
pricing system is expected to include an assessment of criteria
such as severity of illness, the extent of unmet need, and the
wider societal impact—including the effect on caregivers and the
quantiﬁcation of health gain [23]. Therefore, for DM medications
it will likely be important to consider not only clinical effects (e.g.,
glycemic control, systolic blood pressure, and total cholesterol)
and side effects (e.g., hypoglycemic events and weight gain) of
treatment but also other aspects of value such as process-related
elements (e.g., improved patient convenience), societal beneﬁts
(e.g., reduced impact on family members), and level of
innovation.
It is also important to consider how the value of patient
beneﬁts could be recognized within the HTA framework. In DM,
this could relate to an improved patient experience through the
use of a better delivery device or regimen. In Taiwan, for new
drugs approved as category 2 (moderate improvement or similar
therapeutic value), and where the Dosage Regimen Ratio method
is used to determine the drug price, there can be a price premium
of up to 15% if the drug is more convenient or has other
advantages (e.g., better route of administration and longer dosing
interval).2. Availability of local epidemiologic, cost, and quality-of-
life data
It is highly preferable that local economic evaluations attempt to
capture the epidemiologic proﬁle of the relevant population and
that they also include local cost data; country-speciﬁc utility data
should be included if a cost-utility approach is being taken.
There are currently gaps in the cost data. For example, there
are limited cost data on the economic burden of DM in mainland
China, although recent initiatives, such as the study by Le et al.
[24], which quantiﬁed the direct, indirect, and intangible costs in
the rural Yunnan province of China, are attempting to bridge this
gap. Further information is needed, not only on the overall
economic burden of DM but also on the cost of managing DM
and associated complications, so that these can be incorporated
in economic analyses. It is important to recognize that some
costs of DM fall on social care or community budgets and that
these also need to be considered within the perspective of the
analysis.
Regarding the availability of utility data, there are a number of
studies in which the EuroQol ﬁve-dimensional questionnaire has
been used in patients with DM, for example, in Korea [25], Japan
[26], mainland China [27], and Taiwan [14]. Five-level EuroQol
ﬁve-dimensional questionnaires are available in Chinese (tradi-
tional and simpliﬁed), Korean, and Japanese. In Korea, data from
the Korea National Health and Nutrition Examination Survey IV
(20072009) were used to quantify the relationship between DM
and utility [28]. A recent study involving 2257 patients with T2DM
from mainland China, Korea, Malaysia, Thailand, and Taiwan
reported that mean EuroQol ﬁve-dimensional questionnaire
scores were signiﬁcantly lower for patients who had
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 1 0 8 – 1 1 6114hypoglycemic symptoms versus those who did not (0.88 vs. 0.90,
P o 0.0001) [29]. It is important to assess whether utility values
exist for all key DM health states.
Where appropriate, it is necessary that studies be undertaken
to address evidence gaps so that future analyses can more
accurately cover the costs and beneﬁts of a treatment in that
speciﬁc health care environment. The development of local data
should be encouraged and rewarded, as is the case in Taiwan
where a maximum premium of 10% can be added to the price of a
therapy if a local pharmacoeconomic study has been undertaken
as part of the evidence-generation package.
3. Acceptance of modeling as a core methodology to project long-
term outcomes and comparative effectiveness, and to provide
insight on economic impact including cost-offset and
budget impact
In a chronic condition such as DM, mathematical models are
often used to estimate the impact on lifetime health outcomes
[30]. The need for such an approach was recently acknowledged
in the American Diabetes Association Consensus Panel Guide-
lines for Computer Modelling of Diabetes and its Complications
[31]. The use of such models has been accepted by groups such as
the National Institute for Health and Care Excellence in their
assessment of DM technologies. There are examples of economic
models being used to extrapolate long-term outcomes and costs
in Asia. For example, Pollock et al. [32] developed a discrete
event-simulation model to estimate long-term clinical and cost
outcomes in Japanese patients with DM treated with a rapid-
acting insulin analog compared with regular human insulin;
rapid-acting insulin signiﬁcantly reduced cardiovascular compli-
cations over 5 and 10 years, resulting in increased quality of life
and decreased costs.
4. Availability of real-life patient data in DM to capture costs
and beneﬁts in clinical practice
We should also recognize that the assessment of technologies
will not be restricted to launch and that there will be increasing
emphasis on the need for ongoing demonstration of value
through evidence generation. DM disease registries and data-
bases are available in some geographies. The Japan Diabetes
Clinical Data Management Study Group initiative involves the
collection of clinical data from 60 to 70 specialists covering up to
35,000 patients and a range of DM indicators. A recent study
reported on the time and costs of newly registered outpatients
with T2DM [33], while another study assessed the efﬁcacy and
safety of switching Japanese patients with T2DM from neutral
protamine Hagedorn insulin to an insulin analog [34]. In Taiwan,
the National Health Insurance Research Database, which was
launched in 1995, contains registration ﬁles and original claim
data for reimbursement. Large databases derived from this
system are accessed by scientists in Taiwan for research pur-
poses. Access to real-life effectiveness data can help to inform
both the evidence-based management of patients with DM and
ongoing funding decisions, but in some geographies, access to
observational patient data can be limited.
5. Assessment of the speciﬁc evidence requirements of
biosimilars
An area in which HTA and the DM therapeutic disease state are of
particular interest is follow-on biologics or biosimilars. Speciﬁ-
cally, several DM manufacturers are currently developing bio-
similar insulins, and it is anticipated that these will be on the
market in the near future. It is acknowledged that there are
challenges around the HTA evidence requirements for biosimi-
lars [35]. In Korea, there is a government pricing policy forbiosimilars: for a small-molecule drug, the price is 53% of the
innovative product price, and for the larger-molecule drug, it is
70%; clinical evidence of purity, quality, efﬁcacy, and tolerability
is required, and safety should be similar to the original drug. The
assessment of biosimilars is a key area for consideration beyond
the region. For example, a recent (October 2013) consultation
exercise was undertaken by the Canadian Agency for Drugs and
Technologies in Health on the establishment of a Common Drug
Review procedure and process for reviewing subsequent entry
biologics [36]. In addition, the Association of the British Pharma-
ceutical Industry released a position paper on biosimilar medi-
cations in February 2013, which argued that they should be
subject to HTA [37].
Implications for the Future
HTA has the potential to assist payors in making informed
decisions about the coverage of DM medications. It is possible,
however, that a poorly designed or managed HTA process runs
the risk of denying patients appropriate access to medical
technologies, inefﬁciently allocating resources, constraining clin-
ical freedom, and sending distorted signals to medical technology
providers [38]. It is important that the key HTA principles, as
deﬁned by The International Group for HTA Advancement [22],
are followed and that the system is designed to capture the full
value of medication. In DM, the analysis should include all
relevant costs and beneﬁts over the long term. It is also imper-
ative that the impact on the patient of both DM and the
medication is considered. It should be emphasized that the aim
of this article was to provide a forward-looking perspective on
speciﬁc considerations for the assessment of DM medications
within evolving HTA systems. We are not aware of any published
articles that have documented the recent HTA experience of DM
therapies in these geographies, but we recognize that an
appraisal of speciﬁc examples would be a valuable addition to
our understanding.
A second round of evidence-based evaluation of drugs after
the regulatory hurdle can delay or impair patient access to
medications. In South Korea, following the introduction of the
PLS, there was a delay in the time to market entry, and these
effects were greater for new chemical entities than for incremen-
tally modiﬁed drugs [39]. There are some concerns that the new
three-stage system in Taiwan, which requires consensus at both
the consultant meeting and the Pharmaceutical Beneﬁt and Price
Schedule Stakeholders’ meeting and includes the possibility of
re-review, could delay patient access to new medications. It will
be important for this situation to be closely monitored, and ways
of streamlining the process explored. If HTA is to have a formal
future role in mainland China and Japan, there needs to be
agreement on how the ﬁndings of the assessment would inﬂu-
ence health care decision making, and how this could be
implemented without compromising patient access or other
important principles such as equity. Furthermore, building and
maintaining an HTA system is a highly resource-intensive activ-
ity, and endeavors should be made to ensure that the system has
adequate capacity.Conclusions
In summary, to ensure that HTA is an effective mechanism, it is
necessary to develop systems that adequately capture the costs
and beneﬁts of treatments that are important to patients,
physicians, and payors. International alliances and examples of
best practice will provide important insights; however, individual
governments need to develop approaches and systems that meet
local needs and expectations. This is especially pertinent in DM,
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 1 0 8 – 1 1 6 115for which the human and economic burden is great and growing,
and for which new effective therapies provide wide-ranging
beneﬁts to patients and to society as a whole.
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